Technical Analysis for AGEN - Agenus Inc.

Grade Last Price % Change Price Change
F 2.92 0.00% 0.00
AGEN closed unchanged on Thursday, April 22, 2021, on approximately normal volume.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Up
Historical AGEN trend table...

Date Alert Name Type % Chg
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
Doji - Bearish? Reversal 0.00%
BB Squeeze Ended Range Expansion 0.00%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
Slingshot Bearish Bearish Swing Setup 0.00%
Crossed Above 20 DMA Bullish 0.00%
Bollinger Band Squeeze Range Contraction 0.00%
BB Squeeze Started Range Contraction 0.00%
Oversold Stochastic Weakness 0.00%
Bullish Engulfing Bullish 9.16%
Older End-of-Day Signals for AGEN ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Up 2% about 7 hours ago
60 Minute Opening Range Breakout about 7 hours ago
Rose Above Upper Bollinger Band about 8 hours ago
Up 1% about 8 hours ago
Down 3% about 10 hours ago
View Earlier Intraday Alerts

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Agenus Inc. Description

Agenus Inc., a biotechnology company, engages in developing and commercializing technologies to treat cancers and infectious diseases. Its technology portfolio consists of saponin adjuvant based technologies and heat shock protein based technologies. The company offers Oncophage vaccine for the treatment of renal cell carcinoma in patients at intermediate risk of recurrence. Its products under development include QS-21 Stimulon adjuvant, which is in Phase III clinical trials for the treatment of malaria, melanoma, non-small cell lung cancer, and shingles, as well as for the treatment of various infectious diseases, multiple cancer types, and Alzheimer's disease; and HerpV, a therapeutic vaccine candidate that is in Phase 2 clinical trial for the treatment of genital herpes. The company's products under development also comprise Prophage series of cancer vaccines, including R-series candidates in RCC, M-series candidates in melanoma, and G-series candidates in glioma. Its Prophage series of cancer vaccines were tested in Phase III clinical trials for the treatment of renal cell carcinoma and metastatic melanoma; and are in Phase I and Phase II clinical trials for various indications, and in Phase II clinical trials for the treatment of diagnosed and recurrent glioma. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.


Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Cancer Clinical Medicine Infectious Diseases Cancers Small Cell Lung Cancer Melanoma Non Small Cell Lung Cancer Alzheimer's Disease Carcinoma Vaccine Vaccination Ingles Herpes Renal Cell Carcinoma Cancer Vaccine Shingles Malaria Cancer Vaccines Glioma Metastatic Melanoma Oncophage Agenus Experimental Cancer Treatments Genital Herpes Herpes Simplex Research

Is AGEN a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 5.95
52 Week Low 2.28
Average Volume 3,588,716
200-Day Moving Average 3.73
50-Day Moving Average 3.35
20-Day Moving Average 2.77
10-Day Moving Average 2.72
Average True Range 0.20
ADX 21.81
+DI 22.64
-DI 22.31
Chandelier Exit (Long, 3 ATRs ) 2.59
Chandelier Exit (Short, 3 ATRs ) 3.10
Upper Bollinger Band 3.00
Lower Bollinger Band 2.54
Percent B (%b) 0.82
BandWidth 16.89
MACD Line -0.13
MACD Signal Line -0.19
MACD Histogram 0.0516
Fundamentals Value
Market Cap 555.24 Million
Num Shares 190 Million
EPS -0.91
Price-to-Earnings (P/E) Ratio -3.22
Price-to-Sales 6.60
Price-to-Book 0.00
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 3.18
Resistance 3 (R3) 3.17 3.07 3.13
Resistance 2 (R2) 3.07 3.01 3.08 3.12
Resistance 1 (R1) 3.00 2.97 2.95 3.01 3.11
Pivot Point 2.90 2.90 2.88 2.91 2.90
Support 1 (S1) 2.83 2.84 2.78 2.83 2.73
Support 2 (S2) 2.73 2.80 2.74 2.72
Support 3 (S3) 2.65 2.73 2.71
Support 4 (S4) 2.66